drug
copanlisib hydrochloride
Marketedupdated 3mo agoby Bayer HealthCare Pharmaceuticals Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying copanlisib hydrochloride
- phase3Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
- phase2Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
- —Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 22, 2029
~3.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Mar 29, 2032compositionUS 10383876
- Mar 29, 2032method-of-use (U-2124)US 9636344
- Oct 22, 2029compositionUS RE468563.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 41m ago
Found something off?
comments(0)
5-min edit window · permanent after that